Please assess the completion status of the following clinical trial:

Trial Title: A Randomized Controlled Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* Participant has a well-documented clinical history of epilepsy.~* Participant has a clinical diagnosis of Tuberous Sclerosis Complex (TSC) according to the criteria agreed by the 2012 International TSC Consensus Conference.~* All medications or interventions for epilepsy (including ketogenic diet and any neurostimulation devices for epilepsy) must have been stable for 1 month prior to screening and the participant is willing to maintain a stable regimen throughout the trial.~Key Exclusion Criteria:~* Participant has a history of pseudo-seizures.~* Participant has clinically significant unstable medical conditions other than epilepsy.~* Participant has an illness in the 4 weeks prior to screening or randomization, other than epilepsy, which in the opinion of the investigator could affect seizure frequency.~* Participant has undergone general anesthetic in the 4 weeks prior to screening or randomization.~* Participant has undergone surgery for epilepsy in the 6 months prior to screening.~* Participant is being considered for epilepsy surgery or any procedure involving general anesthesia.~* Participant has been taking felbamate for less than 1 year prior to screening.~* Participant is taking an oral mTOR inhibitor.~* Participant has any known or suspected hypersensitivity to cannabinoids or any of the excipients of the Investigational Medicinal Product (IMP), such as sesame oil.~* Participant has any history of suicidal behavior or any suicidal ideation of type 4 or 5 on the C-SSRS in the last month or at screening.~* Participant is currently using or has in the past used recreational or medicinal cannabis, or cannabinoid-based medications, within the 3 months prior to screening and is unwilling to abstain for the duration for the study.~* Participant has tumor growth which, in the opinion of the Investigator, could affect the primary endpoint.~* Participant has significantly impaired hepatic function at the screening or randomization visit~* Participant has received an IMP within the 12 weeks prior to the screening visit.

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 25 mg/kg/day GWP42003-P (Type: EXPERIMENTAL): 100 mg/mL GWP42003-P oral solution taken twice daily (morning and evening).
- 50 mg/kg/day GWP42003-P (Type: EXPERIMENTAL): 100 mg/mL GWP42003-P oral solution taken twice daily (morning and evening).
- Placebo (Type: PLACEBO_COMPARATOR): Placebo oral solution matching 100 mg/mL GWP42003-P.

Based on this trial design, predict the completion outcome and termination type (if applicable).